Impact on Daily Practice Is Completely Unknown

Data from a phase 2 study support further development of sacituzumab tirumotecan plus pembrolizumab in metastatic castration-resistant prostate cancer.

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

Among patients with locally advanced/metastatic urothelial cancer who received at least one 2.2 mg/kg dose of BL-B01D1, the confirmed ORR was 44.1%.

“Paradigm-changing events” are occurring across the small cell lung cancer field in real time, according to Anne Chiang, MD, PhD.

Definitive concurrent chemoradiation followed by consolidation durvalumab in the absence of progression remains the standard of care for stage III NSCLC.